ARDS Evidence based strategies DR. AMITH SREEDHARAN Aster mims , Kannur
History In 1967, Ashbaugh and colleagues reported the clinical characteristics of 12 patients with sudden respiratory failure that they called ARDS No underlying cardiac or pulmonary disease Rapidly developed acute hypoxemia, stiff lungs, and diffuse bilateral alveolar infiltrates on chest x-ray a few days following exposure to a precipitating factor. Autopsies revealed a characteristic histological pattern of diffuse alveolar damage (DAD) including hyaline membrane formation, oedema , cell necrosis, or fibrosis ( Ashbaugh et al. 1967 )
10% ICU PATIENTS 23% MECHANICALLY VENTILATED PATIENTS MORTALITY IN SEVERE ARDS – 46% COGNITIVE DECLINE ,DEPRESSION ,PTSD ,MUSCLE WEAKNESS
FIVE KEY CLINICAL FEATURES PRESENCE OF DEFINED RISK FACTOR SEVERE HYPOXEMIA REFRACTORY TO SUPPLEMENTAL OXYGEN BILATERAL PULMONARY INFILTRATES REDUCED LUNG COMPLIANCE ABSENCE OF CHF
LUNG INJURY SCORE MURRAY 1988 P/F RATIO PEEP COMPLIANCE RADIOGRAPHIC DISTRIBUTION INVALIDATED AS A MARKER OF MORTALITY
First clinical definition - AECC (1994) Acute onset of hypoxemia PaO 2 to FiO 2 ratio ≤ 200 mmHg regardless of PEEP level, Presence of bilateral infiltrates on chest radiograph, and Pulmonary artery wedge pressure ≤ 18 mmHg or no clinical signs of cardiogenic pulmonary oedema ALI ( acute lung injury) ARDS
CRITIQUE VARIABILITY IN PLAIN FILM INTERPRETATION POOR CORRELATION WITH CT CLINICAL ARDS PATIENTS HAD ELEVATED PCWP NO STANDARDISATION OF PEEP ALI ARDS DISTINCTION - ? SIGNIFICANCE
BERLIN definition (2012)
Timing of onset By definition, respiratory symptoms must commence within 7 days of a clinical insult Disease processes developing over several weeks like idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis and granulomatosis with polyangiitis can be excluded by accurately timing the respiratory symptoms
Diseases with acute onset that may mimic ARDS CONGESTIVE HEART FAILURE INTERSTITIAL LUNG DISEASE CONNECTIVE TISSUE DISEASE DIFFUSE ALVEOLAR HEMORRHAGE – ANTI GBM DRUG INDUCED LUNG DISEASE ENDOBRONCHIAL TUBERCULOSIS MALIGNANCY A complete diagnostic workup should include Echo , BAL and chest CT scan
ARDS is an acute inflammatory lung condition ARDS is not a disease Always precipitated by an underlying process
Pathophysioogy ARDS is characterized by a marked reduction in lung compliance DAD is the morphological hallmark of the lung in ARDS Diffuse alveolar damage is defined by the presence of hyaline membranes associated with interstitial oedema , cell necrosis and proliferation and then fibrosis at a later stage
INTERSTITIAL AND ALVEOLAR EDEMA TO FIBROSIS EXUDATIVE PHASE – INITIAL RESPONSE TO INJURY INNATE IMMUNE CELL MEDIATED DAMAGE OF ALVEOLAR ENDOTHELIAL AND EPITHELIAL BARRIERS – EDEMA FLUID WITHIN ALVEOLUS PROLIFERATIVE PHASE - REPAIR PROCESS – RESTORE ALVEOLAR ARCHITECTURE FIBROTIC PHASE - FINAL PHASE – NOT IN ALL PROLONGED MECHANICAL VENTILATION AND INCREASED MORTALITY
Normal lung Hyaline membranes Fibrosis Alveolar hemorrhage
Mechanisms of hypoxemia in ARDS Loss of lung volume due to alveolar oedema and collapse intrapulmonary shunt and marked alteration in (VA/Q ratio) Surfactant deficiency impairment to the hypoxic pulmonary vasoconstriction response Pulmonary hypertension and positive pressure ventilation Opening of patent foramen ovale intracardiac shunt Increase in the physiological dead space occurs Alteration in lung diffusion
Traditional ventilator settings TV 12 – 15 ml/kg PEEP 0 - 5 CM H20 FiO2 0.8 - 1.0 PaCO2 < 50, PO2 > 80, spO2 > 98% Ventilator induced lung injury(VILI)
“Baby lung” Using CT scan, Gattinoni found that compliance correlated with the normally aerated lung and that the specific compliance ( compliance divided by functional residual capacity ) was actually norma l. The "baby lung" is a physiological concept The remaining normally aerated lung accessible to ventilation is considerably reduced and of similar size as that of a baby ARDS lung is not "stiff" but instead small , with nearly normal intrinsic elasticity
“Baby lung” concept
Volutrauma
Effect of PEEP
TREATMENT STRATEGIES
Oxygenation strategies The first-line strategy in supporting hypoxemic patients is to provide oxygen oxygen mask oxygen mask plus reservoir High flow canula – 1 st line strategy for oxygenation
HFNC
The FLORALI study a small multicenter , open-label trial acute hypoxaemic respiratory failure and without hypercapnia, treatment with high-flow nasal oxygen, standard face mask oxygen, or non-invasive ventilation did not result in a significantly different intubation rates. There was a significant difference in favour of high-flow nasal oxygen in 90 day mortality (Frat et al, 2015; FLORALI study)
NIV No strong evidence for the use of noninvasive ventilation ( NIV) Intubation rates of 40-50% in cases of moderate and severe ARDS Risk of delaying intubation by masking signs of respiratory distress Worsening VILI poor tolerance of the facemask is frequent
When to intubate? Whatever oxygenation strategy is used, intubation should not be delayed . RR > 35-40 breaths/min Clinical signs of respiratory distress Severe hypoxemia defined as PaO 2 < 60 mm Hg or SpO 2 < 90% despite high FiO 2 Respiratory acidosis, and copious secretions Non-respiratory indications for invasive ventilation are altered consciousness and the occurrence of shock
Targets of mechanical ventilation To achieve adequate gas exchange whilst avoiding VILI
Lung protective ventilation Low VTs ( 4 - 6 ml/kg of ideal body weight) High PEEP levels ( 11- 16 cm h2O) Strict monitoring of plateau pressure to avoid exceeding 30 cm H2O
Mode of ventilation Worldwide assist-control in volume-controlled ventilation (VCV ) is the most commonly used mode No difference in outcomes between VCV and (PCV Whatever the ventilator mode used, VTs and end-inspiratory plateau pressure should be limited and continuously monitored.
Gas exchange targets Target a PaO2 of at least 60 mm Hg and SaO2 of at least 90% No studies have shown that increasing PaO2 improves outcome Protective ventilation using low VTs may induce respiratory acidosis pH should usually be maintained above 7.2.
Driving pressure Driving pressure ( plateau pressure – PEEP) major determinant of outcome it has been suggested that the mechanical power transferred to the respiratory system from the ventilator plays a key factor in VILI Not only the strain (change in lung volume) but both high flow and respiratory rate are potentially harmful to the lungs
Rescue therapies to improve oxygenation
Recruitment maneuvers Transient increases in trans-pulmonary pressure in an attempt to open collapsed alveoli. When performing a recruitment manoeuvre the pressure reached at the end of inspiration surpasses the recommended safety thresholds for short time periods Sigh breaths, extended sigh breaths, Increased inspiratory pressures and PEEP, Sustained inflation Staircase Recruitment Manoeuvre . There is currently minimal evidence to recommend a particular method of recruitment.
Recruitment maneuvers Oxygenation benefits may be short-lived and of uncertain signifiance , There are no studies showing patient outcome benefits, It is uncertain how to differentiate responders from non-responders There is no evidence for when, how often they should be performed There is no evidence of reducing VILI The ART trial found increased mortality with staircase recruitment manoeuvre . Experts made recently a conditional recommendation for using recruitment maneuver ( Fan et al. 2017 ) Recruitment maneuvers can be considered as rescue therapy in the most severely hypoxemic patients No single method can be recommended.
Proning Advocated for almost 40 years Oxygenation improves dramatically The dorsum of the lung has a larger volume than the anterior and apical areas Better ventilating the dorsal regions of the lung in the prone position improves ventilation, reduces intrapulmonary shunt leading to an improvement in V/Q matching.
Prone position ventilation
Prone ventilation
Hemodynamics of proning Afterload to the right ventricle is reduced Lower pulmonary vascular resistance Reduced levels of PEEP Improves preload
Prone ventilation
PROSEVA Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun . MCRCT n =466 patients with severe ARDS (PaO 2 /Fi0 2 ratio <150 mm Hg, with FiO 2 of at least 0.6, PEEP at least 5 cmH2), and VT 6 ml/kg of IBW) prone-positioning sessions of at least 16 hours duration (n=237) with the supine position (n=229) primary outcome: 28-day mortality lower in the prone group (16% versus 32.8%; P<0.001; hazard ratio for death 0.39, 95% CI 0.25 to 0.63) secondary outcomes: — Unadjusted 90-day mortality lower with prone positioning (23.6% versus 41.0%; P<0.001; hazard ratio 0.44, 95% CI 0.29 to 0.67); NNT=6 — incidence of cardiac arrests higher in the supine group — no difference in ICU LOS or other complications such as pneumothorax — better oxygenation, lower oxygen requirements, and more ventilation-free days in prone group commentary: — highly select group: <15% of all patients with ARDS and <1/3 of screened patients with ARDS underwent randomization, almost 60% ineligible on the basis of exclusion criteria — benefit may be because of long duration proning — mortality among controls (32.8%) was similar to the mortality of 25 to 40% observed in various trials
PROSEVA trial PROSEVA: Prone Positioning in Severe Acute Respiratory Distress Syndrome Guerin et al for the PROSEVA Study Group. NEJM 2013;368:2159-68. Proning in severe ARDS reduces mortality without an increase in adverse outcomes. Further studies are required to confirm these findings but in the mean time these results are difficult to ignore
Early application of airway pressure release ventilation may reduce the duration of mechanical ventilation in acute respiratory distress syndrome Zhou. Intensive Care Medicine 2017; 43:1648-1659 .
APRV (Airway Pressure Release Ventilation)
ECMO CESAR EOLIA Early transfer to ecmo centre and VV ecmo improve survival
CESAR TRIAL 2009 180 patients – ECMO / Conventional 63% survival at 6months in ECMO group Vs 47% in conventional group Technically flawed due to different levels of care Summary : Mortality difference observed cannot be attributed to ECMO
EOLIA TRIAL 2018 NO MORTALITY DIFFERENCE – ECMO VS CONVENTIONAL VENTILATION CONTROLS – 90% PRONE VENTILATED PRONE VS ECMO 28% OF CONTROLS (SICKER AT RANDOMISATION) MIGRATED TO ECMO WHICH MADE RESULTS DIFFICULT TO INTERPRET SUMMARY(HARDIN &HIBBERT 2018,NEJM)): TRIAL SUPPORTS USE OF ECMO WHO HAVE CLEARLY EXCEEDED CONVENTIONAL VENTILATION AND PRONE POSITION
Sedation The use of sedation improves patient tolerance of positive pressure ventilation and allows resting of respiratory muscles and the reduction of oxygen consumption by these muscles.
Neuro muscular blockers Neuromuscular blocking agent cisatracurium used for 48 hours in severe ARDS patients Improved oxygenation ( ACURASYS trial) Reduced lung and systemic inflammation Improved patient survival after adjusting for confounding factors
Steroids Clear indications for steroid therapy for diseases that may mimic ARDS include Alveolar hemorrhage due to vasculitis, Drug-induced toxic pneumonia with a lymphocytic pattern Organized pneumonia Acute eosinophilic pneumonia
Steroids in ARDS Use of steroids in ARDS is unresolved Mortality was significantly higher when steroid therapy was started 2 weeks after the onset Studies showing beneficial outcomes started low dose steroids early in the course of the disease High doses of steroids has been associated with either worse outcomes
Meduri GU et al. 1998 Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998 Jul 8;280(2):159-65. RCT double blind (placebo controlled) n = 24 inclusion criteria: severe ARDS who failed to improve by day 7 of respiratory failure methylpredisolone VS placebo -> reduction in ICU mortality -> reduced oxygenation requirement -> reduction in MODS score – criticisms: small numbers, differences in baseline characteristics between groups.
Steinberg KP, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network . Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006 Apr 20;354(16):1671-84. MC RCT, n = 180 methylprednisolone for 14 days with taper versus placebo results: reduced shock symptoms reduced ventilator days improved pulmonary compliance NO improvement in survival increased mortality in patient who had had steroids > 14 days increased neuromuscular weakness What about steroids for ARDS prophylaxis? – increase in ARDS and subsequent mortality (weak trend)
Other adjunct therapies HFOV - High frequency oscillatory ventilation - found harmful Inhaled nitric oxide - no proven benefit Restricted fluid regimen - beneficial
adults with moderate-to-severe ARDS early application of HFOV, as compared with a ventilation strategy of low tidal volume and high positive end-expiratory pressure, does not reduce, and may increase, in-hospital mortality
OSCAR trial 2013 non-blinded intention-to-treat MC RCT 795 patients HFOV versus usual care control group outcomes: -> all cause mortality at 28 days was 41.7% vs 41.1% (P=0.85 chi-square test) Commentary and criticisms: — less hemodynamic compromise, lower airway pressures than OSCILLATE and more protocol variation, possibly due to physician judgement limiting the harm from HFOV settings — HFOV groups received more sedatives and muscle relaxants Conclusion: no mortality difference at 1 month
SUMMARY Bed side echo ,BAL and CT thorax for complete work up HFNC is first line oxygenation method in mild ARDS Do not delay intubation Lung protective ventilation strategy Recruitment during early disease as rescue oxygenation Early proning in case of poor response Consider early ecmo if poor response to proning
This Photo by Unknown Author is licensed under CC BY-NC-ND